Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Small Cajal body-specific RNA 4 (SCARNA4)
- Target
- SCARNA4
- Molecular classification
- Other (non-coding RNA), Small nucleolar RNA (snoRNA), H/ACA box snoRNA, Small Cajal body-specific RNA (scaRNA)
01
Overview
Small Cajal body-specific RNA 4 (SCARNA4, also called ACA26) is a non-coding RNA of the H/ACA box snoRNA class that is specifically localized in the Cajal bodies within the cell nucleus. SCARNA4 functions as a guide RNA for the pseudouridylation (conversion of uridine to pseudouridine) of specific uridines (notably U39 and U41) in the U2 spliceosomal small nuclear RNA (snRNA), a key component of the major spliceosome machinery. This modification is important for proper snRNA maturation and efficient pre-mRNA splicing. Like other scaRNAs, SCARNA4 is essential for RNA processing but is not itself a protein-coding gene, nor is it a typical druggable therapeutic target. Emerging evidence links SCARNA4 expression and its small RNA derivatives to cancer biology and immune modulation, supporting utility as a potential biomarker in research, but direct targeting by medical drugs is not established.
- Other names
- ACA26small Cajal body specific RNA 4
02
Biological functions
Guide RNA for post-transcriptional modification (pseudouridylation) of spliceosomal snRNAs (notably U2 snRNA)RNA biogenesis and maturation through modification of RNA polymerase II transcribed small nuclear RNAs (U1, U2, U4, U5, U12)Potential modulation of immune response via small RNA derivatives
03
Disease associations
Reported downregulation in congenital heart disease (tetralogy of Fallot)Role in cancer: small RNA derivatives used as markers for cancer immunity and clinical outcomesInvolved in core gene expression changes in lung tissue from pulmonary arterial hypertension patients
04
Biomarkers
Small RNA derivatives from SCARNA4 as candidate biomarkers in several cancers (prognostic value for cancer immunity and clinical outcome)
Beyond the preview
Go deeper on Small Cajal body-specific RNA 4 (SCARNA4).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Small Cajal body-specific RNA 4 (SCARNA4).